SUPPLEMENTAL INFORMATION

## Synthesis of meta-substituted [<sup>18</sup>F]3-fluoro-4-aminopyridine via direct radiofluorination of pyridine N-oxides

P. Brugarolas<sup>a</sup>, R. Freifelder<sup>b</sup>, S.-H. Cheng<sup>b</sup>, and O. DeJesus<sup>c</sup>

<sup>a</sup>Department of Neurology, The University of Chicago, <sup>b</sup>Department of Radiology, The University of Chicago, <sup>c</sup>Department of Medical Physics, The University of Wisconsin at Madison

\* corresponding author: brugarolas@uchicago.edu

SUPPLEMENTAL METHODS

**Complete experimental procedures** 

SUPPLEMENTAL DATA

Reference NMR data of the used compounds

#### SUPPLEMENTAL FIGURES

Sup. Fig. 1. Fluorination of 3-bromo-4-nitropyridine: **A**. UV HPLC trace. **B**. <sup>1</sup>H, <sup>13</sup>C, <sup>19</sup>F NMR.

Sup. Fig. 2. Fluorination of 3-iodo-4-nitropyridine: A. UV HPLC trace. B. <sup>1</sup>H, <sup>13</sup>C, <sup>19</sup>F NMR.

**Sup. Fig. 3.** Fluorination of 3-bromo-4-nitropyridine N-oxide: **A**. UV HPLC trace. **B**. <sup>1</sup>H, <sup>13</sup>C, <sup>19</sup>F NMR.

Sup. Fig. 4. Fluorination of 3-bromopyridine: A. UV HPLC trace. B. <sup>1</sup>H, <sup>13</sup>C, <sup>19</sup>F NMR.

Sup. Fig. 5. Fluorination of 3-bromopyridine N-oxide: A. UV HPLC trace. B. <sup>1</sup>H, <sup>19</sup>F, <sup>13</sup>C NMR.

**Sup. Fig. 6.** Hydrogenation of 3-fluoro-4-nitropyridine N-oxide. UV HPLC before and after.

Sup. Fig. 7. Radioactive and UV HPLC trace of radiofluorination of 3-bromo-4-nitropyridine N-

oxide (not spiked with reference standard)

#### SUPPLEMENTAL METHODS

All radioactivity procedures were approved by the Office of Radiation Safety at the University of Chicago. All chemicals were ordered from Sigma unless otherwise noted.

#### HPLC conditions (A-F):

**A.** Nucleodur 5 μm, 4.6 x 250 mm C18ec (Macherey-Nagel). Flow 1.4 mL/min. Solvent A: 50 mM NH<sub>4</sub>HCO<sub>3</sub>, pH 8.0. Solvent B: 100% MeOH. Method: 0-2 min: 5% B, 2-6 min: 5-50% B, 6-12 min: 50% B, 12-12.5 min: 50-5% B, 12.5-17 min: 5% B.

B. Nucleodur 5 μm, 4.6 x 250 mm C18ec (Macherey-Nagel). Flow 1.4 mL/min. Solvent A: 50 mM NH<sub>4</sub>HCO<sub>3</sub>, pH 8.0. Solvent B: 100% MeOH. Method: 0-2 min: 1% B, 2-9 min: 1-20% B, 9-11 min: 20% B, 11-11.5 min: 20-1% B, 11.5-14 min: 5% B.

**C.** Eclipse XDB 5 μm, 9.4 x 250 mm C18 column (Agilent). Flow 4: mL/min. Mobile phase: 50 mM NaH<sub>4</sub>PO<sub>4</sub>, 10 mM triethylamine, pH 8.0, 5% EtOH. Isocratic: 0-20 min.

**D.** Eclipse XDB 5 μm, 9.4 x 250 mm C18 column (Agilent). Flow: 4 mL/min. Solvent A: 50 mM NH<sub>4</sub>HCO<sub>3</sub>, pH 8.0. Solvent B: 100% MeOH. Method: 0-14 min: 5% B, 14-17 min: 5-25% B, 17-19 min: 25% B, 19-20 min: 25-5% B, 20-25 min: 5% B.

**E.** Eclipse XDB 5 μm, 9.4 x 250 mm C18 column (Agilent). Flow 4: mL/min. Mobile phase: 50 mM NaH<sub>4</sub>PO<sub>4</sub>, 10 mM triethylamine, pH 8.0, 5% EtOH. Isocratic: 0-10 min.

**F.** Acclaim 5 μm, 4.6 x 150 mm C18 column (Thermo Scientific). Flow 0.6: mL/min. Mobile phase: H<sub>2</sub>O 0.1% TFA, 5% MeOH. Isocratic: 0-6 min.

**RadioTLC analysis:** The radioactive sample was spotted on a 25 \* 75 mm TLC plate (PE SIL G, Whatman) next to the non-radioactive standard (1 mg/mL). The TLC was run in 95:5 methanol:acetic acid. The reference standard was visualized using a handheld UV-lamp and the radioactive stop measured with radio-TLC scanner (Eckert & Ziegler).

**Non-radioactive fluorination of 3-bromo-4-nitropyridine (3):** 10  $\mu$ L of 1 M tetrabutylammonium fluoride (TBAF) solution in THF (10  $\mu$ mol, 0.5 eq.) was added to a solution of 3-bromo-4-nitropyridine (96%, Aurum Pharmatech, LLC) (20  $\mu$ mol, 1 eq.) in 500  $\mu$ L of anhydrous dimethylsulfoxide (DMSO) in a 2 mL HPLC vial. The reaction was analyzed by HPLC (conditions A). Retention times: 3-bromo-4-nitropyridine (**3**) = 10.83 min, 3-fluoro-4-nitropyridine = 8.38, 3-bromo-4-fluoropyridine (**6**) = 11.76 min. Retention times for the product matched within 0.05 min the reference standard. Identity of the product was confirmed by HR-MS (*m/z M*<sup>+</sup> exp.: 174.9423, calc: 174.9433) and <sup>1</sup>H, <sup>13</sup>C and <sup>19</sup>F NMR. Product amount was calculated from the area under the curve of the HPLC UV1 trace using a calibration curve.

**Non-radioactive fluorination of 3-iodo-4-nitropyridine (4):** 10 µL of 1 M TBAF solution in THF (10 µmol, 0.5 eq.) was added to a solution of 3-iodo-4-nitropyridine (96%, Aurum Pharmatech, LLC) (20 µmol, 1 eq.) in 500 µL of anhydrous dimethylsulfoxide (DMSO) in a 2 mL HPLC vial. The reaction was analyzed by HPLC (conditions A). Retention times: 3-iodo-4-aminopyridine (**4**) = 11.02 min, 3-iodo-4-fluoropyridine (**7**) = 13.43 min. Starting material absorbs at 254 and 313 nm. Product does not absorb at 313 nm. The product Identity of the product was confirmed by HR-MS (*m/z M*<sup>+</sup> exp.: 222.9288, calc: 222.9294) and <sup>1</sup>H, <sup>13</sup>C and <sup>19</sup>F NMR.

**Non-radioactive fluorination of 3-bromopyridine N-oxide (8):** 10 µL of 1 M TBAF solution in THF (10 µmol, 0.5 eq.) was added to a solution of a 3-bromo-4-nitropyridine N-oxide (98+%, Alfa Aesar) (20 µmol, 1 eq.) in 500 µL of anhydrous DMSO in a 2 mL HPLC vial. The reaction was analyzed by HPLC (conditions B). Retention times: 3-bromo-4-nitropyridine N-oxide (8) = 11.84 min, 3-fluoro-4-nitropyridine N-oxide (9) = 7.93 min. Retention time for the product matched within 0.05 min the reference standard. Identity of the product was confirmed by HR-MS (*m/z M*<sup>+</sup> exp.: 158.0141, calc.: 158.0128) and <sup>1</sup>H, <sup>13</sup>C and <sup>19</sup>F NMR. Product amount was calculated from the area under the curve of the HPLC UV2 trace using a calibration curve.

**Reaction of 3-bromopyridine (11) with TBAF:** 120 μL of 1 M TBAF solution in THF (120 μmol, 1.2 eq.) was added to a solution of a 3-bromopyridine (97%, Combi-Blocks) (100 μmol, 1 eq.) in

400  $\mu$ L of anhydrous DMSO in a 2 mL HPLC vial. The reaction was heated to 120 C for 30 min and analyzed by HPLC (conditions F) and <sup>1</sup>H, <sup>13</sup>C and <sup>19</sup>F NMR. Retention times: 3-bromopyridine (**11**) = 4.31 min, 3-fluoropyridine (**12**) = 1.56 min. No product was detected by HPLC or NMR.

**Reaction of 3-bromopyridine N-oxide (13) with TBAF:** 120  $\mu$ L of 1 M TBAF solution in THF (120  $\mu$ mol, 1.2 eq.) was added to a solution of a 3-bromopyridine N-oxide (97%, Alfa-Aesar) (100  $\mu$ mol, 1 eq.) in 400  $\mu$ L of anhydrous DMSO in a 2 mL HPLC vial. The reaction was heated to 120 C for 30 min and analyzed by HPLC (conditions F) and <sup>1</sup>H, <sup>13</sup>C and <sup>19</sup>F NMR. Retention times: 3-bromopyridine N-oxide (**13**) = 3.46 min, 3-fluoropyridine N-oxide (**14**) = 1.42 min. Yield was determined based on <sup>1</sup>H-NMR and HPLC.

**Catalytic hydrogenation of 3-fluoro-4-nitropyridine N-oxide (9):** 0.1 mg of 3-fluoro-4aminopyridine N-oxide (9) were dissolved in 4 mL of MeOH in a 50 mL round bottom flask containing a stir bar. While stirring, 3-4 mg of 10% Pd/C (dry basis) was added and the flask sealed with a rubber septum. The vial was evacuated and backfilled with hydrogen gas from a balloon and the mixture was allowed to react for 10 min. After 10 min, the suspension was passed through a 0.4 µm PTFE filter and analyzed by HPLC (conditions C). Reference retention times: 3-fluoro-4-aminopyridine N-oxide (9) = 5.80 min, 3-fluoro-4-aminopyridine (10) = 7.05 min. Retention time for the product matched within 0.05 min the reference standard. Identity of the product was confirmed by HR-MS ( $m/z M^+$  exp.: 112.0416, calc: 112.0437). Product amount was calculated from the area under the curve of the HPLC UV2 trace using a calibration curve.

**Procurement of [<sup>18</sup>F]fluoride:** Cyclotron produced no-carrier-added aqueous [<sup>18</sup>F]fluoride was obtained from IBA Molecular North America, Inc.

**Production of tetrabutyl ammonium** [<sup>18</sup>**F**]**fluoride ([**<sup>18</sup>**F**]**TBAF):** Fifty to a hundred mCi (1.85 – 3.7 GBq) of cyclotron produced <sup>18</sup>F<sup>-</sup> were trapped in a Sep-Pak Accell Plus QMA Plus Light Cartridge (Waters Corporation) preconditioned with 5 mL of 50 mM of KHCO<sub>3</sub> followed by 10 mL of water and 20 mL of air. The cartridge was eluted with a solution containing of 300  $\mu$ L of 50

4

mM TBA-HCO<sub>3</sub> in water with 5% EtOH (ABX advanced biochemical compounds GmbH) and 600  $\mu$ L of acetonitrile (MeCN). The water-MeCN solution was dried azeotropically at 85 °C under reduced pressure (20 mbar) for 7.5 min. To ensure complete dryness two additional aliquots of MeCN (500  $\mu$ L) followed by evaporation (3 min) were performed. After drying, the vial was filled with argon gas and cooled down to room temperature in a water beaker. The [<sup>18</sup>F]TBAF residue was dissolved in 100-400  $\mu$ L of anhydrous DMSO and used for the reactions. Radiochemical synthesis of [<sup>18</sup>F]3-fluoro-4-nitropyridine N-oxide ([<sup>18</sup>F]9) from 3-bromo-4nitropyridine N-oxide (8): 100  $\mu$ L of 3-bromo-4-nitropyridine N-oxide (8) dissolved in DMSO (20 mg/mL) were added to 100  $\mu$ L of [<sup>18</sup>F]TBAF solution (~10 mCi, ~370 MBq) in 3 mL microreactor vial and allowed to react for 15 min. 100  $\mu$ L of this solution with or without reference standard (20  $\mu$ g) were injected into a semiprep C-18 HPLC column equipped with a variable wavelength UV-Vis detector and a radiation detector (conditions C). The radioactive peaks were collected and the radioactivity of each fraction measured using a Capintec dose calibrator. The radiochemical yield was calculated as radioactivity in the peak corrected for decay over radioactivity injected.

Radiochemical synthesis of [<sup>18</sup>F]3-fluoro-4-nitropyridine N-oxide ([<sup>18</sup>F]9) from 3-fluoro-4nitropyridine N-oxide (9) by <sup>19</sup>F/<sup>18</sup>F exchange: 100  $\mu$ L of 3-fluoro-4-nitropyridine N-oxide (9) dissolved in DMSO (1 mg/mL) were added to 100  $\mu$ L of [<sup>18</sup>F]TBAF solution (~10 mCi, ~370 MBq) in 3 mL microreactor vial and allowed to react for 1 min. 100  $\mu$ L of this solution were injected into a semiprep C-18 HPLC column equipped with a variable wavelength UV-Vis detector and a radiation detector (conditions E). The radioactive peaks were collected and the radioactivity of each fraction measured using a Capintec dose calibrator. The radiochemical yield was calculated as radioactivity in the peak corrected for decay over radioactivity injected.

**Synthesis of [<sup>18</sup>F]3-fluoro-4-aminopyridine ([<sup>18</sup>F]10):** 1-10 mCi (37-370 MBq) of [<sup>18</sup>F]3-fluoro-4-aminopyridine N-oxide ([<sup>18</sup>F]9) containing 20-100 μg of cold 3-fluoro-4-aminopyridine N-oxide were dissolved in 4 mL of MeOH and the reaction was carried out as described above. The

5

presence of cold compound facilitated obtaining reproducible yields. The product was purified by semiprep HPLC (conditons D). The final specific activity was 10-100 mCi/µmol (0.37-3.7 GBq/µmol).

#### SUPPLEMENTAL DATA

### Reference NMR data of the used compounds.

## 3-bromo-4-nitropyridine (3):

<sup>1</sup>H-NMR ( $d_6$ -DMSO, 500 MHz)  $\delta$  (ppm): 8.06 (1H, t, J = 1.3 Hz), 8.85 (1H, d, J = 1.3 Hz), 9.11 (1 H, s). <sup>13</sup>C-NMR ( $d_6$ -DMSO, 125 MHz)  $\delta$ : (ppm) 110.1 (s), 118.5 (s), 150.8 (s), 150.9 (s), 154.3 (s).

## 3-iodo-4-nitropyridine (4):

<sup>1</sup>H-NMR (*d*<sub>6</sub>-DMSO, 500 MHz) δ (ppm): 7.99 (1H, d, *J* = 5.2 Hz), 8.80 (1H, d, *J* = 5.2 Hz), 9.23 (1 H, s). <sup>13</sup>C-NMR (*d*<sub>6</sub>-DMSO, 125 MHz) δ (ppm): 83.5 (s), 118.2 (s), 150.0 (s), 158.4 (s), 159.8 (s).

## 3-fluoro-4-nitropyridine (5):

<sup>1</sup>H-NMR ( $d_6$ -DMSO, 500 MHz)  $\delta$  (ppm): 8.13 (1H, t, J = 6.2 Hz), 8.75 (1H, d, J = 5.25 Hz), 9.03 (1 H, d, J = 2.9 Hz). <sup>13</sup>C-NMR ( $d_6$ -DMSO, 125 MHz)  $\delta$  (ppm): 118.4 (d, J = 4.8 Hz), 141.8 (d, J = 23.1 Hz), 141.9 (d, J = 23.1 Hz), 147.5 (d, J = 6.7 Hz), 149.7 (d, J = 269.5 Hz). <sup>19</sup>F-NMR ( $d_6$ -DMSO, 470 MHz)  $\delta$  (ppm): -135.13 (dd,  $J_2 = 8.9$  Hz,  $J_1 = 2.5$  Hz).

## 3-bromo-4-fluoropyridine (6):

<sup>1</sup>H-NMR (*d*<sub>6</sub>-DMSO, 500 MHz) δ (ppm): 7.50 (1H, dd,  $J_2 = 9.0$  Hz,  $J_1 = 5.5$  Hz), 8.56 (1H, dd,  $J_2 = 7.5$  Hz,  $J_1 = 5.5$  Hz), 8.81 (1 H, J: 9.5 Hz). <sup>13</sup>C-NMR (*d*<sub>6</sub>-DMSO, 125 MHz) δ (ppm): 106.0 (s), 112.9 (d, J: 16.2 Hz), 151.1 (d, J: 6.2 Hz), 153.5 (s), 165.0 (d, J: 275.4 Hz). <sup>19</sup>F-NMR (*d*<sub>6</sub>-DMSO, 470 MHz) δ (ppm): -99.1 (dd,  $J_2 = 16.9$  Hz,  $J_1 = 9.1$  Hz).

## 3-bromo-4-nitropyridine N-oxide (8):

<sup>1</sup>H-NMR ( $d_6$ -DMSO, 500 MHz)  $\delta$  (ppm): 8.15 (1H, d, J = 7.1 Hz), 8.38 (1H, dd,  $J_2 = 7.1$  Hz,  $J_1 = 2.0$  Hz), 8.85 (1 H, d, J = 1.9 Hz). <sup>13</sup>C-NMR ( $d_6$ -DMSO, 125 MHz)  $\delta$  (ppm): 100? (s), 122.8 (s), 139.2 (s), 142.7 (s), 154.3 (s).

#### 3-fluoro-4-nitropyridine N-oxide (9):

<sup>1</sup>H-NMR (*d*<sub>6</sub>-DMSO, 500 MHz) δ (ppm): 8.24 (1H, dd,  $J_2 = 31.6$  Hz,  $J_1 = 0.8$  Hz), 8.25 (1H, dd,  $J_2 = 35.1$  Hz,  $J_1 = 1.8$  Hz), 8.91 (1 H, dd,  $J_2 = 7.1$  Hz,  $J_1 = 1.8$  Hz). <sup>13</sup>C-NMR (*d*<sub>6</sub>-DMSO, 125 MHz) δ (ppm): 122.3 (s), 131.4 (s), 131.7 (s), 137.0 (d, J = 4.3 Hz), 153.3 (d, J = 264.8 Hz). <sup>19</sup>F-NMR (*d*<sub>6</sub>-DMSO, 470 MHz) δ (ppm): -126.7 (dd,  $J_2 = 8.5$  Hz,  $J_1 = 0.8$  Hz).

### 3-bromopyridine (11):

<sup>1</sup>H-NMR (*d*<sub>6</sub>-DMSO, 500 MHz) δ (ppm): 7.38 (1H, dd,  $J_2 = 8.1$  Hz,  $J_1 = 3.5$  Hz), 7.85 (1H, dt,  $J_2 = 8.2$  Hz,  $J_1 = 1.0$  Hz), 8.56 (1 H, m), 8.69 (1 H, d, J = 2.3 Hz). <sup>13</sup>C-NMR (*d*<sub>6</sub>-DMSO, 125 MHz) δ (ppm): 120.3 (s), 124.9 (s), 138.2 (s), 147.6 (s), 150.1 (s).

### 3-fluoropyridine (12):

<sup>1</sup>H-NMR ( $d_6$ -DMSO, 500 MHz)  $\delta$  (ppm): 7.40 (1H, m), 7.60 (1H, dt,  $J_2 = 7.5$  Hz,  $J_1 = 1.5$  Hz), 8.41 (1 H, m), 8.50 (1 H, d, J = 3.0 Hz). <sup>13</sup>C-NMR ( $d_6$ -DMSO, 125 MHz)  $\delta$  (ppm): 122.8 (d, J =17.7 Hz), 124.9 (d, J = 3.9 Hz), 137.7 (d, J = 22.5 Hz), 145.8 (d, J = 4.1 Hz), 159.2 (d, J = 252.8Hz). <sup>19</sup>F-NMR ( $d_6$ -DMSO, 470 MHz)  $\delta$  (ppm): -126.7 (t, J = 5.1 Hz).

## 3-bromopyridine N-oxide (13):

<sup>1</sup>H-NMR ( $d_6$ -DMSO, 500 MHz)  $\delta$  (ppm): 7.37 (1H, t, J = 7.8 Hz), 7.58 (1H, d, J = 7.6 Hz), 8.25 (1 H, d, J = 7.1 Hz), 8.56 (1 H, s). <sup>13</sup>C-NMR ( $d_6$ -DMSO, 125 MHz)  $\delta$  (ppm): 120.0 (s), 127.0 (s), 128.3 (s), 138.3 (s), 140.0 (s).

#### 3-fluoropyridine N-oxide (14):

<sup>1</sup>H-NMR (*d*<sub>6</sub>-DMSO, 500 MHz) δ (ppm): 7.40 (1H, dt,  $J_2 = 55.4$  Hz,  $J_1 = 7.9$  Hz), 7.42 (1H, dd,  $J_2 = 54.5$  Hz,  $J_1 = 7.2$  Hz), 8.13 (1 H, d, J = 6.4 Hz), 8.51 (1 H, s). <sup>13</sup>C-NMR (*d*<sub>6</sub>-DMSO, 125 MHz) δ (ppm): 113.2 (d, J = 20.4 Hz), 126.6 (d, J = 10.0 Hz), 129.2 (d, J = 35.5 Hz), 136.2 (s), 160.2 (d, J = 247.9 Hz). <sup>19</sup>F-NMR (*d*<sub>6</sub>-DMSO, 470 MHz) δ (ppm): -122.1 (td,  $J_2 = 5.3$  Hz,  $J_1 = 0.8$  Hz).

## SUPPLEMENTAL DATA

## Sup. Fig. 1. Fluorination of 3-bromo-4-nitropyridine.

## 1A. UV HPLC trace



Elution times:

3-bromo-4-nitropyridine (**3**): 10.85 min – absorbs at 254 and 313 nm 3-bromo-4-fluoropyridine (**6**): 11.88 min – absorbs only at 254 nm

#### 1B. NMR



# <sup>19</sup>F NMR



## Sup. Fig. 2. Fluorination of 3-iodo-4-nitropyridine

### 2A. UV HPLC trace



Elution times: 3-iodo-4-nitropyridine (**4**): 10.98 min – absorbs at 254 and 313 nm 3-iodo-4-fluoropyridine (**7**): 13.38 min – absorbs only at 254 nm

#### 2B. NMR <sup>1</sup>H NMR



# <sup>19</sup>F NMR



Sup. Fig. 3. Fluorination of 3-bromo-4-nitropyridine N-oxide



3A. UV HPLC trace

Elution times:

3-bromo-4-nitropyridine N-oxide (8): 11.83 min – absorbs at 254 and 313 nm 3-fluoro-4-nitropyridine N-oxide (9): 7.95 min – absorbs only at 254 and 313 nm

## 3B. NMR

<sup>1</sup>H NMR





Sup. Fig. 4. Fluorination of 3-bromopyridine:









70 60

80

40

50

30 20

10 ppm

190 180 170 160 150 140 130 120 110 100 90

<sup>19</sup>F NMR



Sup. Fig. 5. Fluorination of 3-bromopyridine N-oxide:





#### 5B. NMR

<sup>1</sup>H NMR



<sup>19</sup>F NMR





# <sup>13</sup>C NMR (replicate reaction sample)

Sup. Fig. 6. UV HPLC traces hydrogenation of 3-fluoro-4-nitropyridine N-oxide (before and after)



**Sup. Fig. 7.** Radioactive and UV HPLC trace of radiofluorination of 3-bromo-4-nitropyridine N-oxide (not spiked with reference standard)



Product elutes at 11.6 min and precursor elutes at 17.2 min.

HPLC conditions: Eclipse XDB 5 μm, 9.4 x 250 mm C18 column (Agilent). Flow: 4 mL/min. Solvent A: 50 mM NH<sub>4</sub>HCO<sub>3</sub>, pH 8.0. Solvent B: 100% MeOH. Method: 0-13 min: 5% B, 13-14 min: 5-25% B, 14-20 min: 25% B, 20-21 min: 25-5% B, 21-30 min: 5% B.